PTPA and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, treatment with imatinib, inhibition of SET, or pharmacological activation of PP2A lead to inactivation and degradation of BCR-ABL1 and, consequently, the loss of tumorigenic activity in BCR-ABL1-positive cells, including TKI-resistant CML stem cells [62].